{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:07:16Z","timestamp":1793689636715,"version":"4.5.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Istanbul University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      This study aims to assess\n                      <jats:sup>68<\/jats:sup>\n                      Ga-Trivehexin PET\/CT for detecting hyperfunctioning parathyroid tissue in comparison to [\n                      <jats:sup>99m<\/jats:sup>\n                      Tc]Tc-MIBI scintigraphy-SPECT\/CT (MIBI scan) in patients with primary hyperparathyroidism (PHPT).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The cohort comprised 13 patients diagnosed with PHPT based on biochemical analyses, including serum calcium, phosphorus, and parathyroid hormone\u00a0(PTH) levels. Each participant underwent cervical ultrasonography, MIBI scan, and\n                      <jats:sup>68<\/jats:sup>\n                      Ga-Trivehexin PET\/CT imaging. Complementary 4D-CT and [\n                      <jats:sup>18<\/jats:sup>\n                      F]fluorocholine PET\/CT were conducted in 7 patients. Ten lesions of 7 patients underwent PTH wash-out (WO) procedure.\n                      <jats:sup>68<\/jats:sup>\n                      Ga-Trivehexin PET\/CT findings were compared with other modalities and PTH-WO results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ten patients had sporadic PHPT, while 3 were diagnosed with MEN-1 syndrome-associated PHPT. One patient did not have any identifiable parathyroid lesion across the imaging modalities. On a patient-based analysis, MIBI scan and\n                      <jats:sup>68<\/jats:sup>\n                      Ga-Trivehexin PET\/CT identified parathyroid lesions in 10 and 11 patients, respectively. However,\n                      <jats:sup>68<\/jats:sup>\n                      Ga-Trivehexin PET\/CT detected 7 additional parathyroid lesions that were negative on the MIBI scan. Consequently, 17 lesions were identified and confirmed as hyperfunctioning parathyroid tissue through imaging, PTH-WO, or a combination of both modalities. In lesion-based evaluation,\n                      <jats:sup>68<\/jats:sup>\n                      Ga-Trivehexin identified 16 lesions compared to 10 by MIBI scan, resulting in a detection rate of 94.1% and 58.8%, respectively. Notably, in three patients who underwent [\n                      <jats:sup>18<\/jats:sup>\n                      F]fluorocholine PET\/CT, no lesions were detected; yet\n                      <jats:sup>68<\/jats:sup>\n                      Ga-Trivehexin PET\/CT successfully identified parathyroid lesions in two of these patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Our study provides the first evidence that\n                      <jats:sup>68<\/jats:sup>\n                      Ga-Trivehexin PET\/CT can effectively identify hyperfunctioning parathyroid tissue with a high detection rate warranting further investigations to comprehensively explore its potential in PHPT management.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-024-06846-z","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:01:26Z","timestamp":1721347286000},"page":"3912-3923","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["68Ga-Trivehexin PET\/CT: a promising novel tracer for primary hyperparathyroidism"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1158-5361","authenticated-orcid":false,"given":"Serkan","family":"Kuyumcu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8270-9480","authenticated-orcid":false,"given":"Dilara","family":"Denizmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6945-2003","authenticated-orcid":false,"given":"Duygu","family":"Has-Simsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8851-1109","authenticated-orcid":false,"given":"Arzu","family":"Poyanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0478-1193","authenticated-orcid":false,"given":"Ay\u015fe Kubat","family":"Uzum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9766-1491","authenticated-orcid":false,"given":"Fikret","family":"Buyukkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3786-8052","authenticated-orcid":false,"given":"Emine Goknur","family":"Isik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1384-630X","authenticated-orcid":false,"given":"Semen","family":"Onder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1323-6587","authenticated-orcid":false,"given":"Nihat","family":"Aksakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0360-358X","authenticated-orcid":false,"given":"Zeynep Gozde","family":"Ozkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-2379","authenticated-orcid":false,"given":"Yasemin","family":"Sanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"key":"6846_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(09)60507-9","volume":"374","author":"WD Fraser","year":"2009","unstructured":"Fraser WD. Hyperparathyroidism Lancet. 2009;374:145\u201358.","journal-title":"Hyperparathyroidism Lancet"},{"key":"6846_CR2","doi-asserted-by":"crossref","unstructured":"Silva BC, Cusano NE, Bilezikian JP. Primary hyperparathyroidism. Best practice & research Clinical endocrinology & metabolism. 2018;32:593\u2013607.","DOI":"10.1016\/j.beem.2018.09.004"},{"key":"6846_CR3","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jamasurg.2016.2310","volume":"151","author":"SM Wilhelm","year":"2016","unstructured":"Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh Q-Y, et al. The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg. 2016;151:959\u201368.","journal-title":"JAMA Surg"},{"key":"6846_CR4","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1007\/s00423-022-02648-9","volume":"407","author":"C Lenschow","year":"2022","unstructured":"Lenschow C, Wennmann A, Hendricks A, Germer C-T, Fassnacht M, Buck A, et al. Questionable value of [99mTc]-sestamibi scintigraphy in patients with pHPT and negative ultrasound. Langenbeck\u2019s Archives Surg. 2022;407:3661\u20139.","journal-title":"Langenbeck\u2019s Archives Surg"},{"key":"6846_CR5","doi-asserted-by":"crossref","unstructured":"Weiyun P, Zhi L, Qun L, Peisong W, Guang C. Analysis of causes and treatment strategies for false positive and false negative of 99mTc-MIBI SPECT: Experience sharing and Literature review. 2019 10th International Conference on Information Technology in Medicine and Education (ITME): IEEE; 2019. pp. 23\u20137.","DOI":"10.1109\/ITME.2019.00016"},{"key":"6846_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.surg.2021.05.056","volume":"171","author":"CE Graves","year":"2022","unstructured":"Graves CE, Hope TA, Kim J, Pampaloni MH, Kluijfhout W, Seib CD, et al. Superior sensitivity of 18F-fluorocholine: PET localization in primary hyperparathyroidism. Surgery. 2022;171:47\u201354.","journal-title":"Surgery"},{"key":"6846_CR7","doi-asserted-by":"crossref","unstructured":"Talbot J-N, P\u00e9ri\u00e9 S, Tassart M, Delbot T, Aveline C, Zhang-Yin J et al. 18F-fluorocholine PET\/CT detects parathyroid gland hyperplasia as well as adenoma: 401 PET\/CTs in one center. Q J Nuclear Med Mol Imaging. 2023;30.","DOI":"10.23736\/S1824-4785.23.03513-6"},{"key":"6846_CR8","first-page":"468","volume":"38","author":"P Thakral","year":"2023","unstructured":"Thakral P, Das SS, Dhiman S, Manda D, Virupakshappa C, Malik D, Sen I. Validation of in-house kit-like synthesis of 68Ga-Trivehexin and its biodistribution for targeting the integrin \u03b1v\u03b26 expressing tumors. Cancer Biother Radiopharm. 2023;38:468\u201374.","journal-title":"Cancer Biother Radiopharm"},{"key":"6846_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/embor.2009.276","volume":"11","author":"C Margadant","year":"2010","unstructured":"Margadant C, Sonnenberg A. Integrin\u2013TGF-\u03b2 crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 2010;11:97\u2013105.","journal-title":"EMBO Rep"},{"key":"6846_CR10","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.1158\/0008-5472.CAN-07-0245","volume":"67","author":"AN Elayadi","year":"2007","unstructured":"Elayadi AN, Samli KN, Prudkin L, Liu Y-H, Bian A, Xie X-J, et al. A peptide selected by biopanning identifies the integrin \u03b1v\u03b26 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res. 2007;67:5889\u201395.","journal-title":"Cancer Res"},{"key":"6846_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1172\/JCI200523183","volume":"115","author":"RC Bates","year":"2005","unstructured":"Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, et al. Transcriptional activation of integrin \u03b26 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Investig. 2005;115:339\u201347.","journal-title":"J Clin Investig"},{"key":"6846_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature21035","volume":"542","author":"X Dong","year":"2017","unstructured":"Dong X, Zhao B, Iacob RE, Zhu J, Koksal AC, Lu C, et al. Force interacts with macromolecular structure in activation of TGF-\u03b2. Nature. 2017;542:55\u20139. https:\/\/doi.org\/10.1038\/nature21035","journal-title":"Nature"},{"key":"6846_CR13","doi-asserted-by":"publisher","first-page":"e003465","DOI":"10.1136\/jitc-2021-003465","volume":"10","author":"P Busenhart","year":"2022","unstructured":"Busenhart P, Montalban-Arques A, Katkeviciute E, Morsy Y, Van Passen C, Hering L, et al. Inhibition of integrin \u03b1v\u03b26 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer. J Immunother Cancer. 2022;10:e003465. https:\/\/doi.org\/10.1136\/jitc-2021-003465","journal-title":"J Immunother Cancer"},{"key":"6846_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000005278","author":"SS Das","year":"2024","unstructured":"Das SS, Ahlawat S, Thakral P, Malik D, Simecek J, Cb V, et al. Potential efficacy of 68Ga-Trivehexin PET\/CT and immunohistochemical validation of \u03b1v\u03b26 integrin expression in patients with head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma. Clin Nucl Med. 2024. https:\/\/doi.org\/10.1097\/rlu.0000000000005278","journal-title":"Clin Nucl Med"},{"key":"6846_CR15","doi-asserted-by":"crossref","unstructured":"Quigley NG, Steiger K, Hober\u00fcck S, Czech N, Zierke MA, Kossatz S et al. PET\/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the cancer integrin \u03b1v\u03b26 with Ga-68-Trivehexin. Eur J Nucl Med Mol Imaging. 2021:1\u201312.","DOI":"10.21203\/rs.3.rs-719213\/v1"},{"key":"6846_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06750-6","author":"J Rehm","year":"2024","unstructured":"Rehm J, Winzer R, Notni J, Hempel S, Distler M, Folprecht G, Kotzerke J. Concomitant metastatic head-and-neck cancer and pancreatic cancer assessed by \u03b1v\u03b26-integrin PET\/CT using 68Ga-Trivehexin: incidental detection of a brain metastasis. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-06750-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6846_CR17","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1007\/s00259-021-05334-y","volume":"48","author":"P Petranovi\u0107 Ov\u010dari\u010dek","year":"2021","unstructured":"Petranovi\u0107 Ov\u010dari\u010dek P, Giovanella L, Carri\u00f3 Gasset I, Hindi\u00e9 E, Huellner MW, Luster M, et al. The EANM practice guidelines for parathyroid imaging. Eur J Nucl Med Mol Imaging. 2021;48:2801\u201322. https:\/\/doi.org\/10.1007\/s00259-021-05334-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6846_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s12262-016-1489-7","volume":"79","author":"ZG Ozkan","year":"2017","unstructured":"Ozkan ZG, Unal SN, Kuyumcu S, Sanli Y, Gecer MF, Ozcinar B, et al. Clinical utility of Tc-99m MIBI SPECT\/CT for preoperative localization of parathyroid lesions. Indian J Surg. 2017;79:312\u20138. https:\/\/doi.org\/10.1007\/s12262-016-1489-7","journal-title":"Indian J Surg"},{"key":"6846_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00259-023-06573-x","volume":"51","author":"G Treglia","year":"2024","unstructured":"Treglia G, Rizzo A, Piccardo A. Expanding the clinical indications of [(18)F]fluorocholine PET\/CT in primary hyperparathyroidism: the evidence cannot be evaded. Eur J Nucl Med Mol Imaging. 2024;51:1345\u20138. https:\/\/doi.org\/10.1007\/s00259-023-06573-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6846_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1530\/eje-21-0038","volume":"185","author":"F Bioletto","year":"2021","unstructured":"Bioletto F, Barale M, Parasiliti-Caprino M, Prencipe N, Berton AM, Procopio M, et al. Comparison of the diagnostic accuracy of 18F-Fluorocholine PET and 11\u00a0C-Methionine PET for parathyroid localization in primary hyperparathyroidism: a systematic review and meta-analysis. Eur J Endocrinol. 2021;185:109\u201320. https:\/\/doi.org\/10.1530\/eje-21-0038","journal-title":"Eur J Endocrinol"},{"key":"6846_CR21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/mnm.0000000000000952","volume":"40","author":"WAM Broos","year":"2019","unstructured":"Broos WAM, van der Zant FM, Knol RJJ, Wondergem M. Choline PET\/CT in parathyroid imaging: a systematic review. Nucl Med Commun. 2019;40:96\u2013105. https:\/\/doi.org\/10.1097\/mnm.0000000000000952","journal-title":"Nucl Med Commun"},{"key":"6846_CR22","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s00259-017-3911-1","volume":"45","author":"E Quak","year":"2018","unstructured":"Quak E, Blanchard D, Houdu B, Le Roux Y, Ciappuccini R, Lireux B, et al. F18-choline PET\/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT\/CT are negative or inconclusive: the APACH1 study. Eur J Nucl Med Mol Imaging. 2018;45:658\u201366. https:\/\/doi.org\/10.1007\/s00259-017-3911-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6846_CR23","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00259-018-4123-z","volume":"46","author":"G Treglia","year":"2019","unstructured":"Treglia G, Piccardo A, Imperiale A, Strobel K, Kaufmann PA, Prior JO, Giovanella L. Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019;46:751\u201365. https:\/\/doi.org\/10.1007\/s00259-018-4123-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6846_CR24","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1158\/1541-7786.MCR-08-0568","volume":"7","author":"V Bhatia","year":"2009","unstructured":"Bhatia V, Mula RV, Weigel NL, Falzon M. Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase\/Akt signaling. Mol Cancer Res. 2009;7:1119\u201331. https:\/\/doi.org\/10.1158\/1541-7786.MCR-08-0568","journal-title":"Mol Cancer Res"},{"key":"6846_CR25","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.bbrc.2004.11.069","volume":"328","author":"RC Gensure","year":"2005","unstructured":"Gensure RC, Gardella TJ, Juppner H. Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun. 2005;328:666\u201378. https:\/\/doi.org\/10.1016\/j.bbrc.2004.11.069","journal-title":"Biochem Biophys Res Commun"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06846-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06846-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06846-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T05:20:11Z","timestamp":1730352011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06846-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":25,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["6846"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06846-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,19]]},"assertion":[{"value":"24 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by Istanbul University Faculty of Medicine Clinical Research Ethics Committee (Date:22\/04\/2024 File no:2024.850).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study. The authors also affirm that human research participants provided informed consent for publication of the images in all figures included in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no conflicts of interest regarding financial or non-financial relationships that could influence the objectivity of this research. However, we acknowledge that Trivehexin precursor used in this study was provided free of charge by Nukleon Nuclear Technology Research, the local distributor of the manufacturer (Trimt GmBH). This arrangement did not involve any financial contributions or obligations from our part.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}